4.56
+3.17%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shanghai Fudan Forward S&T Co
Its shares trade on Shanghai under the ticker 600624.SS. It has been listed since 5 January 1993. In the fiscal year to 31 December 2025, it reported revenue of CN¥640.1m and a net loss of CN¥197.5m. At that date it held total assets of CN¥1.35bn and shareholders' equity of CN¥438.1m.
Shanghai Fudan Forward S&T Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products. The company is headquartered in Shanghai, Shanghai. The firm's pharmaceuticals include digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, immune function medications and others. The firm is also engaged in the provision of financial insurance software products. The company distributes its products within domestic markets and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 5 Jan 1993
- Employees
- 1,426
- Website
- forwardgroup.com ↗
Leadership
Pay as last reported
- Mr. Zheng SongChairman of the Board, Acting General Manager, since 2023
- Mr. Chihao ZhouFinance Director, Deputy General Manager
- Mr. Yuming ChenDeputy General ManagerCN¥1.3m
- Mr. Hangxiang FuDeputy General Manager
- Mr. Ding ShenDeputy General ManagerCN¥845,600
- Ms. Yue ZhuangDeputy General Manager, since 2020CN¥185,200
- Ms. Min ShenSecretary of the BoardCN¥462,200
- Ms. Yan LiDirector
- Ms. Yan LuDirector
- Ms. Jingyuan ZhangDirector
- Ms. Wei NiIndependent Director
- Mr. Yongkang RenIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shanghai Fudan Forward S&T Co Ltd employs 1,426 full-time employees in Shanghai.
- The company produces digestive system drugs and nervous system drugs in the pharmaceutical sector.
- Shanghai Fudan Forward S&T Co Ltd distributes pharmaceuticals domestically and internationally.
Weaknesses
- The company's financial insurance software products are a secondary business segment.
- Shanghai Fudan Forward S&T Co Ltd has no international headquarters outside China.
- The company's product range is limited to specific pharmaceutical categories.
Opportunities
- Shanghai Fudan Forward S&T Co Ltd can expand its pharmaceutical offerings in the Chinese market.
- The company can leverage its domestic market presence to enter new international markets.
- Shanghai Fudan Forward S&T Co Ltd has potential to grow in the antineoplastic drug segment.
Threats
- Shanghai Fudan Forward S&T Co Ltd faces competition from other Chinese pharmaceutical firms.
- The company's reliance on domestic markets exposes it to economic fluctuations in China.
- Shanghai Fudan Forward S&T Co Ltd must navigate regulatory changes in the pharmaceutical industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.